Democratising AI-empowered drug discovery
with A team shaped by real-world drug development
OUR STORY
Accelerating innovation
AI-enabled drug discovery is no longer theoretical. Programmes leveraging AI are demonstrating meaningful improvements in speed, cost efficiency, and early clinical trial outcomes.
25-50%
Estimated time & cost savings in AI-driven R&D efforts¹
$25.7B
Projected AI market growth in pharma by 2030²
80-90%
Reported Phase I success rates for AI-discovered molecules³
Having contributed to the development of more than 20 FDA-approved drugs, our founding team recognized that not all AI is equal. Algorithms trained without a deep understanding of biological constraints struggle to design molecules that are novel, manufacturable, stable, and clinically actionable.
In 2020, we founded Etcembly to close that gap and create a biologically grounded AI platform that unifies biochemical, structural, and developability insights with machine learning to accelerate and de-risk therapeutic design.
References
-
Wellcome Trust and Boston Consulting Group. Unlocking the potential of AI in drug discovery. Wellcome Trust. Published June 26th, 2023. https://wellcome.org/reports/unlocking-potential-ai-drug-discovery
-
Devereson, Alex, and Navraj Nagra. “How Pharma Is Rewriting the AI Playbook: Perspectives from Industry Leaders.” The Synthesis, November 26, 2025. https://www.mckinsey.com/industries/life-sciences/our-insights/the-synthesis/how-pharma-is-rewriting-the-ai-playbook-perspectives-from-industry-leaders
-
Kp Jayatunga M, Ayers M, Bruens L, Jayanth D, Meier C. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discov Today. 29(6): 104009 (2024). doi: 10.1016/j.drudis.2024.104009
OUR MILESTONES
What we’ve built so far
3
TCR and antibody-specific LLMs fine-tuned/created
4
Patents filed
$20M
In funding raised
